The evolution of factor VIIa in the treatment of bleeding in haemophilia with inhibitors-Reference-Cited by-同舟云学术

The evolution of factor VIIa in the treatment of bleeding in haemophilia with inhibitors

Published:2019-09-05 Issue:6 Volume:25 Page:911-918
ISSN:1351-8216
Container-title:Haemophilia
language:en
Short-container-title:Haemophilia

Author:

Meeks Shannon L.¹,Leissinger Cindy A.²

Affiliation:

1. Department of Pediatrics Aflac Cancer and Blood Disorders Center at Children's Healthcare of Atlanta, Emory University School of Medicine Atlanta GA USA

2. Section of Hematology/Oncology Tulane University School of Medicine New Orleans LA USA

Funder

HEMA Biologics, LLC

Publisher

Wiley

Subject

Genetics (clinical),Hematology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/hae.13845

Reference60 articles.

1. FEIBA versus NovoSeven in Hemophilia Patients with Inhibitors

2. Genentech.Emicizumab‐kxwh safety information.https://www.emicizumabinfo.com/hcp/emicizumab-safety-information.html. Accessed May 7 2019.

3. FeketeLF HolstSL PeetoomF De VeberLI."Auto"‐factor IX concentrate: A new therapeutic approach to treatment of hemophilia A patients with inhibitors [Abstract]. 14th International Congress of Hematology. San Paulo;1972.https://ci.nii.ac.jp/naid/10006804560/en/. Accessed March 13 2019.

4. Use of human factor VIIa in the treatment of two hemophilia A patients with high-titer inhibitors.

5. Therapeutic choices for patients with hemophilia and high-titer inhibitors

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Current status and future prospects of activated recombinant coagulation factor VIIa, NovoSeven®, in the treatment of haemophilia and rare bleeding disorders;Annals of Hematology;2023-06-30

2. Congenital Factor VII Deficiency, Diagnosis, and Management;Congenital Bleeding Disorders;2023

3. Phase III dose selection of marzeptacog alfa (activated) informed by population pharmacokinetic modeling: A novel hemostatic drug;CPT: Pharmacometrics & Systems Pharmacology;2022-10-18

4. Eptacog beta efficacy and safety in the treatment and control of bleeding in paediatric subjects (<12 years) with haemophilia A or B with inhibitors;Haemophilia;2022-04-27

5. Infusão endovenosa domiciliar: tecnologias educativas para o cuidado à pessoa com hemofilia;Acta Paulista de Enfermagem;2022